| Literature DB >> 17082319 |
Jeff S Isenberg1, Fuminori Hyodo, Ken-Ichiro Matsumoto, Martin J Romeo, Mones Abu-Asab, Maria Tsokos, Periannan Kuppusamy, David A Wink, Murali C Krishna, David D Roberts.
Abstract
The nitric oxide (NO)/cGMP pathway, by relaxing vascular smooth muscle cells, is a major physiologic regulator of tissue perfusion. We now identify thrombospondin-1 as a potent antagonist of NO for regulating F-actin assembly and myosin light chain phosphorylation in vascular smooth muscle cells. Thrombospondin-1 prevents NO-mediated relaxation of precontracted vascular smooth muscle cells in a collagen matrix. Functional magnetic resonance imaging demonstrated that an NO-mediated increase in skeletal muscle perfusion was enhanced in thrombospondin-1-null relative to wild-type mice, implicating endogenous thrombospondin-1 as a physiologic antagonist of NO-mediated vasodilation. Using a random myocutaneous flap model for ischemic injury, tissue survival was significantly enhanced in thrombospondin-1-null mice. Improved flap survival correlated with increased recovery of oxygen levels in the ischemic tissue of thrombospondin-1-null mice as measured by electron paramagnetic resonance oximetry. These findings demonstrate an important antagonistic relation between NO/cGMP signaling and thrombospondin-1 in vascular smooth muscle cells to regulate vascular tone and tissue perfusion.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17082319 PMCID: PMC1801044 DOI: 10.1182/blood-2006-08-041368
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113